


## AMENDMENTS TO THE CLAIMS

The following listing of claims will replace all prior versions, and listings, of claims in the application:


1. (Currently Amended) A bicycloamide derivative represented by the following general formula (1):



[wherein]  $R^1$  and  $R^2$  may or may not be identical to one another and are each independently a hydrogen atom, substituted or unsubstituted  $C_1$  to  $C_6$  alkyl group, substituted or unsubstituted  $C_3$  to  $C_6$  cycloalkyl group, substituted or unsubstituted arylmethyl group, substituted or unsubstituted arylethyl group, substituted or unsubstituted aromatic hydrocarbon group, substituted or unsubstituted aromatic heterocyclic ring, substituted or unsubstituted aliphatic heterocyclic ring or  $NR^3R^4$  (wherein  $R^3$  and  $R^4$  may or may not be identical to one another and are each independently a hydrogen atom, substituted or unsubstituted  $C_1$  to  $C_6$  alkyl group, substituted or unsubstituted  $C_3$  to  $C_6$  cycloalkyl group, substituted or unsubstituted arylmethyl group, substituted or unsubstituted aromatic hydrocarbon group, substituted or unsubstituted aromatic heterocyclic ring or substituted or unsubstituted aliphatic heterocyclic

ring, or R<sup>3</sup> and R<sup>4</sup> may together form a ring structure.), structure), or R<sup>1</sup> and R<sup>2</sup> may together form a ring structure; X is CH<sub>2</sub>, CHF, CF<sub>2</sub>, CHO, S or O; and n is 1, 2 or 3.] is 1, 2 or 3, or a pharmaceutically acceptable salt thereof.


2. (Currently Amended) The bicycloamide derivative according to claim 1, represented by the following general formula (2):



[wherein] wherein R<sup>5</sup> is a substituted or unsubstituted C<sub>1</sub> to C<sub>6</sub> alkyl group, substituted or unsubstituted C<sub>3</sub> to C<sub>6</sub> cycloalkyl group, substituted or unsubstituted arylmethyl group, substituted or unsubstituted arylethyl group, substituted or unsubstituted aromatic hydrocarbon group, substituted or unsubstituted aromatic heterocyclic ring, substituted or unsubstituted aliphatic heterocyclic ring or NR<sup>3</sup>R<sup>4</sup> (wherein R<sup>3</sup> and R<sup>4</sup> may or may not be identical to one another and are each independently a hydrogen atom, substituted or unsubstituted C<sub>1</sub> to C<sub>6</sub> alkyl group, substituted or unsubstituted C<sub>3</sub> to C<sub>6</sub> cycloalkyl group, substituted or unsubstituted arylmethyl group, substituted or unsubstituted aromatic hydrocarbon group, substituted or unsubstituted aromatic heterocyclic ring or substituted or unsubstituted aliphatic heterocyclic ring, or R<sup>3</sup> and R<sup>4</sup> may together form a ring structure.), structure); X is CH<sub>2</sub>, CHF, CF<sub>2</sub>, CHO, S or O; and n is 1, 2 or 3.] is 1, 2 or 3,


or a pharmaceutically acceptable salt thereof.

3. (Currently Amended) The bicycloamide derivative according to claim 1, represented by the following general formula (3):



[wherein] wherein R<sup>7</sup> and R<sup>8</sup> may or may not be identical to one another and are each independently a substituted or unsubstituted C<sub>1</sub> to C<sub>6</sub> alkyl group, substituted or unsubstituted C<sub>3</sub> to C<sub>6</sub> cycloalkyl group, substituted or unsubstituted arylmethyl group, substituted or unsubstituted arylethyl group, substituted or unsubstituted aromatic hydrocarbon group, substituted or unsubstituted aromatic heterocyclic ring, substituted or unsubstituted aliphatic heterocyclic ring or NR<sup>3</sup>R<sup>4</sup> (wherein R<sup>3</sup> and R<sup>4</sup> may or may not be identical to one another and are each independently a hydrogen atom, substituted or unsubstituted C<sub>1</sub> to C<sub>6</sub> alkyl group, substituted or unsubstituted C<sub>3</sub> to C<sub>6</sub> cycloalkyl group, substituted or unsubstituted arylmethyl group, substituted or unsubstituted aromatic hydrocarbon group, substituted or unsubstituted aromatic heterocyclic ring or substituted or unsubstituted aliphatic heterocyclic ring, or R<sup>3</sup> and R<sup>4</sup> may together form a ring structure), or R<sup>7</sup> and R<sup>8</sup> may together form a ring structure; X is CH<sub>2</sub>, CHF, CF<sub>2</sub>, CHO, S or O; and n is 1, 2 or 3.] is 1, 2 or 3,  
or a pharmaceutically acceptable salt thereof.

4. (Currently Amended) An intermediate in the production of the bicycloamide derivative of claim 1, represented by the following formula (4):



[wherein] R<sup>1</sup> and R<sup>2</sup> may or may not be identical to one another and are each independently a hydrogen atom, substituted or unsubstituted C<sub>1</sub> to C<sub>6</sub> alkyl group, substituted or unsubstituted C<sub>3</sub> to C<sub>6</sub> cycloalkyl group, substituted or unsubstituted arylmethyl group, substituted or unsubstituted arylethyl group, substituted or unsubstituted aromatic hydrocarbon group, substituted or unsubstituted aromatic heterocyclic ring, substituted or unsubstituted aliphatic heterocyclic ring or NR<sup>4</sup>R<sup>5</sup> (wherein R<sup>4</sup> and R<sup>5</sup> may or may not be identical to one another and are each independently a hydrogen atom, substituted or unsubstituted C<sub>1</sub> to C<sub>6</sub> alkyl group, substituted or unsubstituted C<sub>3</sub> to C<sub>6</sub> cycloalkyl group, substituted or unsubstituted arylmethyl group, substituted or unsubstituted aromatic hydrocarbon group, substituted or unsubstituted aromatic heterocyclic ring or substituted or unsubstituted aliphatic heterocyclic ring, or R<sup>4</sup> and R<sup>5</sup> may together form a ring structure), or R<sup>1</sup> and R<sup>2</sup> may together form a ring structure; X is CH<sub>2</sub>, CHF, CF<sub>2</sub>, CHO, S or O; n is 1, 2 or 3; and P<sup>1</sup> is an amino-protecting group.]

5. (Currently Amended) A pharmaceutical productcomposition, containing as an active ingredient the bicycloamide derivative according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable auxiliary agent.
6. (Currently Amended) A DPP-IV inhibitor, containing as an active ingredient the bicycloamide derivative according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable auxiliary agent.
7. (Currently Amended) A therapeutic agent for treating diseases involving DPP-IV type II diabetes, containing as an active ingredient the bicycloamide derivative according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable auxiliary agent.
8. (Cancelled)
9. (New) A method of treating type II diabetes, which comprises administering to a patient in need of said treatment a therapeutically effective amount of the bicycloamide derivative according to claim 1 or a pharmaceutically acceptable salt thereof.